Outcomes of pancreatic cancer surveillance among high-risk individuals at a tertiary care academic center.

Authors

Alice A Lee, Abigail Twoy, Pradeep Siddappa, Sharon Pneh, Andrea Leung, Naoko Fushimi, Ahmed El Kaffas, Allison W Kurian, Walter G Park

Published in

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]. Jun 30, 2026. Epub Jun 30, 2026.

Abstract

Pancreatic cancer screening is only recommended for those with a strong family history or predisposing hereditary pathogenic variant. For these high-risk individuals (HRIs), practice guidelines recommend annual pancreas surveillance by either endoscopic ultrasound (EUS) or magnetic resonance imaging (MRI). We report HRI surveillance outcomes and tested the hypothesis that HRIs would have substantially more non-malignant pancreatic changes than non-HRIs.
HRIs were included if they met high-risk criteria per major practice guidelines and underwent at least one screening exam. Non-HRI controls were identified as patients undergoing EUS for non-pancreatic indications. Patients' demographic and clinical data including surveillance findings were obtained retrospectively from electronic health records.
278 HRIs were followed for a total of 1454 person-years from 2009 through 2024. During this period, 3 (1.1%) patients were diagnosed with pancreatic ductal adenocarcinoma (PDAC) at stages IA (n = 1) and IV (n = 2), and 2 (0.7%) with high-grade dysplasia (HGD). In a multivariable analysis, HRIs were significantly more likely than non-HRI controls to have incidental non-malignant findings of diffuse echogenicity [OR 3.3, 95% CI (1.5-7.5)], hyperechoic stranding [OR 20.2, 95% CI (7.3-55.8)], hyperechoic foci [OR 37.6, 95% CI (4.9-289.5)], lobularity [OR 9.1, 95% CI (3.8-22.0)], and cysts [OR 63.4, 95% CI (8.2-488.6)] on EUS.
The results highlight the need for cascade genetic testing to identify asymptomatic relatives who carry an identified familial pathogenic variant that confers high pancreatic cancer risk. Further studies are needed to determine the relationship between non-malignant EUS findings and development of PDAC or HGD.

PMID:
42399188
Bibliographic data and abstract were imported from PubMed on 04 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.